What the research found
The brain is approximately 60% fat by dry weight, with omega-3 fatty acids (particularly DHA) being a structural component of neuronal membranes rather than simply a supporting nutrient. Despite this logical foundation, individual supplement interventions have often failed to show expected cognitive benefits in randomized trials—a pattern the author attributes not to ineffective nutrients, but to nutrient interactions.
Evidence from the VITACOG trial illustrates this: B vitamins reduced brain atrophy in older adults with mild cognitive impairment, but only in those with adequate baseline omega-3 status. In participants deficient in omega-3, the same B-vitamin intervention produced minimal benefit. Observational data from the Framingham Offspring cohort found that each additional nutrient gap (omega-3, elevated homocysteine, or low vitamin D) was associated with roughly 50% higher dementia risk, with people deficient in all three carrying approximately 4–5 times the risk of those deficient in none.
The core insight: the brain operates these nutrients as an interconnected system rather than a ranked hierarchy. A single nutritional weakness can neutralize benefits from other interventions—meaning targeted measurement matters more than generic supplement lists.
Why it matters for you
Most MyKine users already track biomarkers and recognize that context determines intervention effectiveness. This framework applies directly: rather than adopting a generic "brain health stack," you'd test omega-3 index, homocysteine, and 25(OH)D to identify your specific gaps before supplementing. The research suggests that a user with low omega-3 may waste resources on B vitamins or vitamin D until that foundation is addressed.
The timing angle is also relevant for your platform. Alzheimer's pathology begins silently roughly 15–20 years before symptoms appear. For women, the perimenopause transition itself accelerates amyloid deposition and gray matter changes—particularly in APOE-ε4 carriers. This means the window for nutrient optimization isn't at 65, but now, and it's measurable today via the three biomarkers mentioned above.
Caveats
- The VITACOG B-vitamin findings are from a secondary analysis stratifying by omega-3 status, not the primary trial design
- The Framingham Offspring data is observational; causation is not established
- The source is behind a paywall for specific dosing, safety guidance, and full evidence grading—key details are withheld here
- Women's Alzheimer's risk involves complex hormonal and genetic factors (APOE status) beyond nutrient gaps alone
- The author notes standard lab reference ranges for homocysteine may be too permissive and flags unnamed safety concerns in B-vitamin protocols that require the full paid content to evaluate